USANA Health Sciences (USNA) Set to Announce Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is set to release its earnings data after the market closes on Tuesday, April 30th. Analysts expect USANA Health Sciences to post earnings of $0.69 per share for the quarter. USANA Health Sciences has set its FY 2024 guidance at 2.400-3.000 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.35. The company had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a return on equity of 13.49%. On average, analysts expect USANA Health Sciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Up 0.2 %

Shares of USANA Health Sciences stock opened at $44.23 on Tuesday. The firm has a market cap of $850.99 million, a PE ratio of 13.40, a price-to-earnings-growth ratio of 1.35 and a beta of 0.91. USANA Health Sciences has a 12-month low of $42.59 and a 12-month high of $69.60. The company’s fifty day simple moving average is $47.51 and its two-hundred day simple moving average is $49.05.

Insider Activity

In other news, insider David Mulham Mulham sold 4,311 shares of USANA Health Sciences stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $47.76, for a total transaction of $205,893.36. Following the sale, the insider now owns 7,825 shares of the company’s stock, valued at approximately $373,722. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider David Mulham Mulham sold 4,311 shares of USANA Health Sciences stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $47.76, for a total transaction of $205,893.36. Following the sale, the insider now owns 7,825 shares of the company’s stock, valued at approximately $373,722. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Kevin Guest sold 11,011 shares of USANA Health Sciences stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.00, for a total transaction of $539,539.00. Following the sale, the chairman now directly owns 10,491 shares in the company, valued at approximately $514,059. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,807 shares of company stock valued at $1,200,791. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

USNA has been the topic of a number of recent analyst reports. DA Davidson cut their price target on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a report on Thursday, February 22nd. StockNews.com raised shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.